

**2015**  
Press release



[www.genfit.com](http://www.genfit.com)

## **GENFIT ANNOUNCES ITS FINANCIAL CALENDAR FOR 2015**

**Lille (France), Boston (Massachusetts, United States), January 27<sup>th</sup>, 2015** – GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces its tentative financial calendar for 2015, which is set as follows:

February 20, 2015:	Publication of revenue for Q4 2014, and cash position as of December 31, 2014
February 24, 2015:	Combined General Shareholders' Meeting in Lille
April 3, 2015:	Publication of 2014 financial statements
May 7, 2015:	Publication of revenue for Q1 2015, and cash position as of March 31, 2015
June 3, 2015:	Annual Shareholders' Meeting in Lille
September 25, 2015:	Publication of financial statements as of June 30, 2015
November 6, 2015:	Publication of revenue for Q3 2015, and cash position as of September 30, 2015

**About GENFIT:**

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH.

With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

**Disclaimer:**

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext of Euronext Paris filed with the AMF, which is available on the AMF website ([www.amf-france.org](http://www.amf-france.org)) or on GENFIT's website ([www.genfit.com](http://www.genfit.com)).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country.

**Contacts**

**GENFIT** | Jean-François Mouney - CEO & Chairman of the Management Board | Ph. +333 2016 4000

**MILESTONES** – Relation Presse | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 – [barabian@milestones.fr](mailto:barabian@milestones.fr)